

Case Report

Abdominal Tumor Requiring Surgical Resection in a Young Patient with Neurofibromatosis Type 1

Tumor Abdominal com Indicação de Ressecção Cirúrgica em Doente Jovem com Neurofibromatose Tipo 1

Victor Costa^{1*}, Hironidina Spencer¹, Pamela Borges¹, Mariana Afonso², Catarina Santos², Carla Barbosa¹, Lúcio Lara Santos²

1. Hospital Universitário Agostinho Neto, Praia, Cabo Verde

2. Instituto Português de Oncologia, Porto, Portugal

Corresponding Author/Autor Correspondente:

Victor Costa [Victor.Costa@huan.gov.cv]

Hospital Universitário Agostinho Neto, Praia, Cabo Verde

<https://doi.org/10.34635/rpc.1137>

ABSTRACT

Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder that affects approximately 1 in 3000 births. Retroperitoneal tumors occur in 2%-5% of NF1 patients and pose diagnostic and therapeutic challenges. We report a 25-year-old male from Cape Verde with confirmed NF1 who presented with progressive abdominal pain and a 15 × 11 × 12 cm retroperitoneal mass in the left psoas muscle. He underwent a successful complete surgical resection. Histologically, it was a malignant peripheral nerve sheath tumor (MPNST), high-grade, with foci of heterologous rhabdomyosarcomatous differentiation (malignant triton tumor). Molecular testing confirmed a likely pathogenic variant (c.288+5G>A) in the *NF1* gene. This case highlights the importance of early diagnosis, appropriate surgical intervention, molecular confirmation for family genetic counseling, and the development of emerging systemic therapies, including targeted treatments for NF1-associated tumors.

Keywords: Neurofibromatosis 1/complications; Retroperitoneal Neoplasms/surgery

Received/Recebido: 30/10/2025 **Accepted/Aceite:** 17/11/2025 **Published online/Publicado online:** 18/12/2025 **Published/Publicado:**

© Author(s) (or their employer(s)) and Portuguese Journal of Surgery 2025. Re-use permitted under CC BY-NC 4.0. No commercial re-use.

© Autor(es) (ou seu(s) empregador(es)) e Revista Portuguesa de Cirurgia 2025. Reutilização permitida de acordo com CC BY-NC 4.0. Nenhuma reutilização comercial.

RESUMO

A neurofibromatose tipo 1 (NF1) é uma doença autossômica dominante que afeta 1 em cada 3000 nascimentos. Os tumores retroperitoneais ocorrem em 2% a 5% dos doentes com NF1 e representam desafios diagnósticos e terapêuticos. Relata-se o caso de um homem de 25 anos, natural de Cabo Verde, com NF1 confirmada, que apresentava dor abdominal progressiva e uma massa retroperitoneal de 15 x 11 x 12 cm no músculo psoas esquerdo. Foi submetido a uma ressecção cirúrgica completa com sucesso. Histologicamente era um tumor das bainhas nervosas periféricas maligno (MPNST), de alto grau, com focos de diferenciação rabdomiossarcomatosa heteróloga (tumor de triton maligno). Os testes moleculares confirmaram uma provável variante patogénica (c. 288+5G>A) no gene *NF1*. Este caso enfatiza a importância do diagnóstico precoce, da intervenção cirúrgica adequada, da confirmação molecular para aconselhamento genético familiar e de terapias sistémicas emergentes, incluindo tratamentos direcionados para tumores associados à NF1.

Palavras-chave: Neoplasias Retroperitoneais/cirurgia; Neurofibromatose 1/complicações

INTRODUCTION

Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous syndrome caused by mutations in the *NF1* gene on chromosome 17q11.2, which encodes neurofibromin, a tumor suppressor protein regulating the RAS-MAPK pathway.^{1,2} The loss of neurofibromin function results in constitutive activation of RAS signaling, leading to increased cell proliferation, survival, and tumor formation.³

Retroperitoneal tumors represent a rare complication (2%-5% of NF1 patients), typically presenting between ages 20-40 years.^{4,5} These tumors pose significant diagnostic challenges regarding malignant transformation and require aggressive surgical management. The lifetime risk of developing malignant peripheral nerve sheath tumors (MPNST) in NF1 patients is 8%-13%, with a particularly poor prognosis.⁶

CASE REPORT

1. PATIENT AND HISTORY

A 25-year-old male from Santiago Island, Cape Verde, with diagnosed NF1 presented in April 2025 with progressive left upper quadrant abdominal pain, significant weight loss, and asthenia. Family history was strongly positive for NF1 (father, aunt, uncle, and paternal grandfather affected).

2. PHYSICAL EXAMINATION

On admission (August 4, 2025) to Hospital Dr. Agostinho Neto, in Cape Verde, the patient was cachectic and dehydrated with:

- Vital signs: BP 117/86 mmHg, HR 148 bpm, temperature 36.5°C
- Skin: Multiple café-au-lait macules and cutaneous neurofibromas

- Abdomen: Large, non-mobile, tender mass in left upper and lower quadrants

3. LABORATORY FINDINGS

- Hemoglobin: 10.7 g/dL (anemia)
- Leukocytes: 17 200/mm³ (leukocytosis)
- Platelets: 589 000/mm³ (thrombocytosis)
- Glucose: 48 mg/dL (hypoglycemia)
- Total proteins: 3.81 g/dL (hypoproteinemia)
- Sodium: 131 mEq/L (hyponatremia)

4. IMAGING

CT scan (April 30, 2025, CIDIS Clinic, Dakar, Senegal) revealed (Fig. 1):

- Heterogeneous mass 15 × 11 × 12 cm in left psoas muscle
- Thickening of multiple nerve roots
- No pulmonary or hepatic metastases
- Radiological diagnosis: neurofibromas with probable sarcomatous degeneration

5. SURGICAL MANAGEMENT

After clinical optimization and correction of metabolic disturbances, the patient underwent exploratory laparotomy with complete tumor resection (Fig. 2).

Intraoperative findings:

- Well-delimited tumor adherent to the left psoas muscle
- No invasion of adjacent structures
- Complete resection with preservation of neurovascular structures

Specimen: 16 × 15 × 10 cm encapsulated mass with firm consistency and lobulated surface



Figure 1 – CT scan reveals a heterogeneous mass 15 × 11 × 12 cm in the left psoas muscle, with thickening of multiple nerve roots. Radiological diagnosis: neurofibromas with probable sarcomatous degeneration.




Figure 2 – Surgical specimen.

Postoperative course: Uneventful recovery without complications

6. HISTOPATHOLOGY

Surgical specimen corresponding to an abdominal tumor fixed in formalin measuring 16x15x10 cm. Upon sectioning, several cavitated areas with necrosis and hemorrhagic regions are observed. Histological examination reveals a densely cellular malignant mesenchymal neoplasm, composed of cells with oval and vesicular nuclei, inconspicuous nucleoli, and scant cytoplasm. The cells are arranged in long bundles, in a "fishbone" pattern, within a richly vascularized stroma, partly fibrillar and partly dense.

In the observed material, nuclear pleomorphism is discreet to moderate, the mitotic index is greater than 20 mitoses/10HPF, and no foci of necrosis are identified.

Immunohistochemical study shows:

- Multifocal positivity for PS100 and CD34
- Focal positivity (rare cells) for desmin
- Loss of expression of H3K27me3 and p16 is observed.

In conclusion it was a malignant peripheral nerve sheath tumor (MPNST), high-grade, with foci of heterologous

rhabdomyosarcomatous differentiation (Malignant Triton tumor) (Fig. 3).

7. MOLECULAR GENETIC TESTING

Testing at Instituto Português de Oncologia at Porto, Portugal, identified a likely pathogenic variant in the *NF1* gene: c.288+5G>A (heterozygous).

Clinical Significance:

- Confirms molecular diagnosis of NF1
- Suspected to cause aberrant splicing (ClinVar ID 642764)
- First-degree relatives have 50% carrier risk
- Enables family cascade screening

DISCUSSION

1. CLINICAL PRESENTATION

Retroperitoneal tumors in NF1 typically grow silently to large dimensions before diagnosis.⁷ This patient presented with classic features: a large tumor (15 cm), pain, cachexia, and constitutional symptoms. The metabolic derangements (anemia, hypoproteinemia, hypoglycemia) reflected a significant tumor burden.




Figure 3 – Malignant peripheral nerve sheath tumor (MPNST), high-grade, with foci of heterologous rhabdomyosarcomatous differentiation (malignant triton tumor).

2. DIFFERENTIAL DIAGNOSIS

Distinguishing benign neurofibromas from malignant peripheral nerve sheath tumors (MPNST) is challenging. Features suggesting malignancy include⁸:

- Size >5 cm (present)
- Rapid growth
- Persistent pain (present)
- Radiological heterogeneity (present)

However, the well-delimited, encapsulated nature and absence of invasion suggest possible benign pathology. Final histopathology will be determinant.

3. MOLECULAR DIAGNOSIS

The c.288+5G>A splice-site variant confirms NF1 diagnosis and enables:

- Family genetic counseling

- Predictive testing for at-risk relatives
- Implementation of appropriate surveillance protocols
- Reproductive planning guidance

Loss of neurofibromin function results in hyperactivation of the RAS-MAPK and mTOR pathways, providing rational targets for systemic therapy.⁹

4. SURGICAL MANAGEMENT

Complete surgical resection with negative margins remains the gold standard for localized retroperitoneal tumors in NF1.¹⁰ Bloc resection with negative intraoperative margins represents optimal management, though long-term outcomes depend on final histopathology.

The systemic treatment options are condensed in Table 1.

Table 1 – The systemic treatment options

Category	Treatment/Topic	Key Information	Bibliography
Conventional Chemotherapy	Overview	Remains the backbone of systemic treatment, though outcomes are generally poor	11
	Doxorubicin-based regimens	Doxorubicin + ifosfamide is the standard first-line regimen Response rates: 15-25% for MPNST Median progression-free survival: 4-6 months	12 13
	Alternative regimens	Gemcitabine + docetaxel: demonstrated activity with better tolerability	14
		Eribulin: approved for liposarcoma and leiomyosarcoma	15
		Trabectedin: active in certain sarcoma subtypes	16
Targeted Therapy: MEK Inhibitors	Rationale	Constitutive activation of RAS-MAPK pathway in NF1	17
	Selumetinib	FDA approved (April 2020) for pediatric patients ≥2 years with NF1 Phase II trial (SPRINT Stratum 1): 71% achieved partial response Clinical trials ongoing for MPNST	18 19 20
	Trametinib	Potent MEK1/2 inhibitor approved for BRAF-mutant melanoma Phase II trial: 40% achieved ≥20% volume reduction	21 22
	Cobimetinib	Under investigation in combination strategies	23
mTOR Inhibitors	Pathway	mTOR pathway dysregulated in NF1-deficient tumors	24
	Sirolimus	Phase II trial: clinical benefit in 82% of patients Combination with MEK inhibitors under investigation	25 26
	Everolimus	Limited single-agent activity, combination strategies being explored	27
Immunotherapy	Checkpoint inhibitors	Limited activity in soft tissue sarcomas including MPNST SARC028 trial: Pembrolizumab showed 18% response rate Combination strategies under investigation	28 29 30
	Adoptive cell therapy	CAR-T cell therapy targeting GD2 in early clinical development	31
Novel Targeted Approaches	HDAC inhibitors	Vorinostat showed preclinical activity	32
	FGFR inhibitors	Preclinical evidence suggests FGFR signaling contribution	33
	Combination strategies	MEK inhibitor + CDK4/6 inhibitor: promising preclinical synergy	34
		MEK inhibitor + HSP90 inhibitor: under investigation Vertical pathway inhibition (MEK + mTOR): rational combination	35 26

Treatment based on Histopathology is condensed in Table 2.

5. SURVEILLANCE RECOMMENDATIONS

Following current guidelines⁴¹, NF1 patients require:

- Clinical examination every 3-6 months for 5 years, then annually
- Imaging (CT or MRI) every 6-12 months for 5 years
- Annual whole-body MRI for new tumor detection (particularly plexiform neurofibromas)
- Monitoring for additional NF1-associated malignancies:
 - Breast cancer screening starting age 30 (annual MRI + mammography)⁴²
 - Annual blood pressure monitoring (pheochromocytoma)
 - Annual ophthalmologic examination (optic pathway gliomas)
- Family cascade screening with genetic counseling

6. CANCER RISKS IN NF1

NF1 patients face significantly increased lifetime risks⁴³:

- MPNST: 8%-13%
- Breast cancer: 20%-40% (females)
- Optic pathway gliomas: 15%-20%
- Gastrointestinal stromal tumors (GIST): 7%
- Pheochromocytoma: 1%-5%
- Rhabdomyosarcoma: increased risk (especially pediatric)
- Various CNS tumors: increased risk

CONCLUSION

This case illustrates a typical retroperitoneal tumor presentation in a young NF1 patient. Key management elements include:

1. Complete surgical resection as the primary curative treatment
2. Molecular confirmation enabling family genetic counseling and cascade screening

Table 2 – Treatment based on Histopathology and prognostic factors.

Category	Condition/Scenario	Management Approach/Details	Bibliography
Treatment Algorithm Based on Histopathology	Benign neurofibroma	Surveillance with clinical examination and imaging every 6-12 months No systemic therapy indicated Consider MEK inhibitor only if symptomatic progression or inoperability	
	ANNUBP	Close surveillance every 3-6 months Consider MEK inhibitor for progressive disease	36
	Localized MPNST with positive margins	Adjuvant radiotherapy (50-60 Gy) Consider adjuvant chemotherapy (controversial, no clear survival benefit) Clinical trial enrollment preferred	37 38
	Unresectable or metastatic MPNST	First-line: Doxorubicin + ifosfamide Second-line: Gemcitabine + docetaxel or clinical trial with MEK inhibitor Consider immunotherapy in checkpoint inhibitor combinations Palliative radiotherapy for symptomatic sites	12 20 30
	Prognosis	Benign tumors Excellent prognosis with complete resection MPNST - Overall Poor prognosis with 5-year survival 20%-50% MPNST - Localized resectable 50%-60% 5-year survival MPNST - Unresectable or metastatic <20% 5-year survival NF1-associated vs sporadic NF1-associated MPNSTs have worse prognosis than sporadic MPNST	6,39 40
	Prognostic Factors	Tumor size >5 cm: worse prognosis Surgical margin status R0 resection critical Tumor grade Affects prognosis Presence of metastases Affects prognosis NF1 status NF1-associated worse than sporadic	

3. Histopathological diagnosis determining prognosis and treatment strategy
4. Emerging targeted therapies, particularly MEK inhibitors like selumetinib, offer new hope for patients with inoperable or progressive disease
5. Multidisciplinary approach essential for optimal outcomes
6. Lifelong surveillance is mandatory due to multiple cancer risks

The integration of surgical expertise, molecular genetics, and novel targeted therapies exemplifies modern management of NF1-associated tumors. For this patient, awaiting final histopathology is critical: if benign, surveillance alone is appropriate; if MPNST is confirmed, consideration of adjuvant therapy and clinical trial enrollment should be discussed. The established efficacy of selumetinib in NF1-associated plexiform neurofibromas¹⁹ and ongoing trials in MPNST²⁰ represent significant therapeutic advances.

Standardized screening protocols, specialized center referral, and participation in clinical trials investigating novel targeted therapies are essential to improve outcomes in this high-risk population.

Malignant triton tumor is a rare and aggressive variant of malignant peripheral nerve sheath tumor (MPNST) characterized by rhabdomyosarcomatous differentiation, accounting for only 5%-10% of all MPNSTs and occurring sporadically or in association with neurofibromatosis type 1 (NF1).⁴⁴ The prognosis is poor, with 5-year survival rates of 10%-15%, high local recurrence rates (40%-60%), and distant metastases developing in 40%-65% of cases, most commonly affecting the lungs and bone.^{44,45} The most critical prognostic factor is achieving negative surgical margins, followed by tumor size (>5 cm portends worse outcomes) and NF1 association.⁴⁶ Treatment centers on wide surgical excision with clear margins as the cornerstone of therapy, typically followed by adjuvant radiation therapy to improve local control. At the same time, the role of chemotherapy remains controversial though it may be considered using sarcoma or rhabdomyosarcoma-based regimens.^{45,47} Intensive post-treatment surveillance is essential due to the high risk of recurrence and metastatic disease, making complete surgical resection the patient's best chance for long-term survival.^{44,45}

ETHICAL DISCLOSURES

Conflicts of Interest: The authors have no conflicts of interest to declare.

Financing Support: This work has not received any contribution, grant or scholarship.

Confidentiality of Data: The authors declare that they have followed the protocols of their work center regarding the publication of patient data.

Patient Consent: Consent for publication was obtained.

Provenance and Peer Review: Not commissioned; externally peer-reviewed.

RESPONSABILIDADES ÉTICAS

Conflitos de Interesse: Os autores declaram a inexistência de conflitos de interesse na realização do presente trabalho.

Fontes de Financiamento: Não existiram fontes externas de financiamento para a realização deste artigo.

Confidencialidade dos Dados: Os autores declaram ter seguido os protocolos da sua instituição acerca da publicação dos dados de doentes.

Consentimento: Consentimento do doente para publicação obtido.

Proveniência e Revisão por Pares: Não comissionado; revisão externa por pares.

CONTRIBUTORSHIP STATEMENT:

The authors: VC, HS, PB, MA, MT, CB, and LLS designed the study and reviewed and edited the manuscript.

All authors approved the final version to be published.

DECLARAÇÃO DE CONTRIBUIÇÃO

Os autores: VC, HS, PB, MA, MT, CB e LLS conceberam o estudo e reviram e editaram o manuscrito.

Todos os autores aprovaram a versão final a ser publicada.

REFERENCES

1. Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. *J Med Genet*. 2007;44:81-8. doi: 10.1136/jmg.2006.045906.
2. Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. *Cell*. 2001;104:593-604.
3. Ratner N, Miller SJ. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. *Nat Rev Cancer*. 2015;15:290-301.
4. Reilly KM, Kim A, Blakely J, Ferner RE, Gutmann DH, Legius E, et al. Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future. *J Natl Cancer Inst*. 2017;109:djx124. doi: 10.1093/jnci/djx124.
5. Khosrotehrani K, Bastuji-Garin S, Riccardi VM, Birch P, Friedman JM, Wolkenstein P. Subcutaneous neurofibromas are associated with mortality in neurofibromatosis 1: a cohort study of 703 patients. *Am J Med Genet A*. 2005;132A:49-53. doi: 10.1002/ajmg.a.30394.
6. Evans DG, Baser ME, McGaughan J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. *J Med Genet*. 2002;39:311-4. doi: 10.1136/jmg.39.5.311.
7. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors: a clinicopathologic study of 120 cases. *Cancer*. 1986;57:2006-21.
8. Farid M, Demicco EG, Garcia R, Ahn L, Merola PR, Cioffi A, et al. Malignant peripheral nerve sheath tumors. *Oncologist*. 2014;19:193-201. doi: 10.1634/theoncologist.2013-0328.
9. Johannessen CM, Reczek EE, James MF, Rems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. *Proc Natl Acad Sci U S A*. 2005;102:8573-8. doi: 10.1073/pnas.0503224102. Erratum in: *Proc Natl Acad Sci U S A*. 2005;102:16119.
10. Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. *Cancer*. 2006;107:1065-74. doi: 10.1002/cncr.22098. PMID: 16881077.
11. Kroep JR, Ouali M, Gelderblom H, Le Cesne A, Dekker TJA, Van Glabbeke M, et al. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. *Ann Oncol*. 2011;22:207-14. doi: 10.1093/annonc/mdq338.
12. Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. *Lancet Oncol*. 2014;15:415-23. doi: 10.1016/S1470-2045(14)70063-4.
13. Valentin T, Fournier C, Penel N, Bompas E, Chaigneau L, Isambert N, et al. Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO). *Invest New Drugs*. 2013;31:1626-7. doi: 10.1007/s10637-013-0023-z.
14. Maki RG, Wathen JK, Patel SR, Priebe DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. *J Clin Oncol*. 2007;25:2755-63. doi: 10.1200/JCO.2006.10.4117.
15. Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. *Lancet*. 2016;387:1629-37. doi: 10.1016/S0140-6736(15)01283-0.
16. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetz SM, Staddon A, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. *J Clin Oncol*. 2016;34:786-93. doi: 10.1200/JCO.2015.62.4734.
17. de Blank PM, Gross AM, Akshintala S, Blakeley JO, Bollag G, Cannon A, et al. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. *Neuro Oncol*. 2022;24:1845-56. doi: 10.1093/neuonc/noac165.
18. U.S. Food and Drug Administration. FDA approves selumetinib for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas. April 10, 2020. [accessed Jan 2025] Available at: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selumetinib-neurofibromatosis-type-1-symptomatic-inoperable-plexiform-neurofibromas>
19. Fisher MJ, Shih CS, Rhodes SD, Armstrong AE, Wolters PL, Dombi E, et al. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. *Nat Med*. 2021;27:165-73. doi: 10.1038/s41591-020-01193-6.
20. Subbiah V, Slopis J, Hong DS. Treatment of patients with advanced neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors (MPNSTs) with the MEK inhibitor cobimetinib. *J Clin Oncol*. 2018;36:11559.
21. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. *N Engl J Med*. 2012;367:107-14. doi: 10.1056/NEJMoa1203421.
22. Weiss BD, Wolters PL, Plotkin SR, Widemann BC, Tonsgard JH, Blakeley J, et al. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametnib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. *J Clin Oncol*. 2021;39:797-806. doi: 10.1200/JCO.20.02220.
23. Perreault S, Larouche V, Tabori U, Hawkin C, Lippé S, Ellezam B, et al. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. *BMC Cancer*. 2019;19:1250. doi: 10.1186/s12885-019-6442-2.
24. Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC, et al. TORC1 is essential for NF1-associated malignancies. *Curr Biol*. 2008;18:56-62. doi: 10.1016/j.cub.2007.11.066.

25. Weiss B, Widemann BC, Wolters P, Dombi E, Vinks A, Cantor A, et al. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. *Neuro Oncol.* 2015;17:596-603. doi: 10.1093/neuonc/nou235. Erratum in: *Neuro Oncol.* 2015;17:905. doi: 10.1093/neuonc/nov068.
26. De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF, et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. *Cancer Cell.* 2011;20:400-13. doi: 10.1016/j.ccr.2011.08.014.
27. Subbiah V, Westin SN, Wang K, Araujo D, Wang WL, Miller VA, et al. Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein. *J Hematol Oncol.* 2014;7:8. doi: 10.1186/1756-8722-7-8.
28. Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetz SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. *Lancet Oncol.* 2017;18:1493-501. doi: 10.1016/S1470-2045(17)30624-1.
29. D'Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. *Lancet Oncol.* 2018;19:416-26. doi: 10.1016/S1470-2045(18)30006-8.
30. Pollack SM, Redman MW, Baker KK, Wagner MJ, Schroeder BA, Loggers ET, et al. Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naïve sarcoma: a phase 1/2 nonrandomized clinical trial. *JAMA Oncol.* 2020;6:1778-82. doi: 10.1001/jamaoncol.2020.3689.
31. Sait S, Modak S. Anti-GD2 immunotherapy for osteosarcoma. *Adv Exp Med Biol.* 2014;804:291-304.
32. Mayes DA, Hu Y, Teng Y, Siegel E, Wu X, Panda K, et al. PAX6 suppresses the invasiveness of glioblastoma cells and the expression of the matrix metalloproteinase-2 gene. *Cancer Res.* 2006;66:9809-17. doi: 10.1158/0008-5472.CAN-05-3877.
33. Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, et al. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target. *Clin Cancer Res.* 2012;18:5020-30. doi: 10.1158/1078-0432.CCR-12-1072.
34. De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. *Nature.* 2014;514:247-51. doi: 10.1038/nature13561.
35. Jousma E, Rizvi TA, Wu J, Janhofer D, Dombi E, Dunn RS, et al. Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1. *Pediatr Blood Cancer.* 2015;62:1709-16. doi: 10.1002/pbc.25546.
36. Miettinen MM, Antonescu CR, Fletcher CD, Kim A, Lazar AJ, Quezado MM, et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. *Hum Pathol.* 2017;67:1-10. doi: 10.1016/j.humpath.2017.05.010.
37. Stucky CC, Johnson KN, Gray RJ, Pockaj BA, Ocal IT, Rose PS, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. *Ann Surg Oncol.* 2012;19:878-85. doi: 10.1245/s10434-011-1978-7.
38. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. *Cancer.* 2008;113:573-81. doi: 10.1002/cncr.23592.
39. Martin E, Muskiewicz KM, Claramunt-Alonso R. Clinical, pathological, and genetic features of malignant peripheral nerve sheath tumor: a systematic review with meta-analysis and pooled mutation analysis. *Front Oncol.* 2022;12:745952.
40. Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G, et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. *J Clin Oncol.* 2005;23:8422-30. doi: 10.1200/JCO.2005.01.4886.
41. Ferner RE, Gutmann DH. Neurofibromatosis type 1 (NF1): diagnosis and management. *Handb Clin Neurol.* 2013;115:939-55.
42. Madanikia SA, Bergner AL, Ye X, Blakeley JO. Increased risk of breast cancer in women with NF1. *Am J Med Genet A.* 2012;158A:3056-60. doi: 10.1002/ajmg.a.35550.
43. Uusitalo E, Rantanen M, Kallionpää RA, Pöyhönen M, Leppävirta J, Ylä-Outinen H, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. *J Clin Oncol.* 2016;34:1978-86. doi: 10.1200/JCO.2015.65.3576.
44. Stasik CJ, Tawfik O. Malignant Peripheral Nerve Sheath Tumor With Rhabdomyosarcomatous Differentiation (Malignant Triton Tumor). *Arch Pathol Lab Med.* 2006;130:1878-81.
45. McConnell YJ, Giacomantonio CA. Malignant triton tumors--complete surgical resection and adjuvant radiotherapy associated with improved survival. *J Surg Oncol.* 2012;106:51-6.
46. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. *Cancer.* 1986;57:2006-21.
47. Orphanet: Malignant triton tumor. Orphanet Report Series. 2014. [accessed Jan 2024] <https://www.orpha.net/en/disease/detail/252212>